{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:57:19Z","timestamp":1791640639448,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:00:00Z","timestamp":1302048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1245\/s10434-011-1695-2","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T20:51:34Z","timestamp":1302036694000},"page":"2833-2840","source":"Crossref","is-referenced-by-count":137,"title":["Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays"],"prefix":"10.1245","volume":"18","author":[{"given":"Kab Choong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Wha","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung-Moon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hwan","family":"Yook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137\u201350.","journal-title":"J Clin Oncol."},{"issue":"Suppl 4","key":"1695_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdp122","volume":"20","author":"C Jackson","year":"2009","unstructured":"Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):34\u20136.","journal-title":"Ann Oncol."},{"key":"1695_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-8722-2-9","volume":"2","author":"M Javle","year":"2009","unstructured":"Javle M, Hsueh CT. Updates in gastrointestinal oncology: insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol. 2009;2:9.","journal-title":"J Hematol Oncol."},{"key":"1695_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/CCO.0b013e32832c42e0","volume":"21","author":"AD Wagner","year":"2009","unstructured":"Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol. 2009;21:381\u20135.","journal-title":"Curr Opin Oncol."},{"key":"1695_CR5","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523\u20139.","journal-title":"Ann Oncol."},{"key":"1695_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000288295","volume":"78","author":"JT Jorgensen","year":"2010","unstructured":"Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26\u201333.","journal-title":"Oncology."},{"key":"1695_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science."},{"key":"1695_CR8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med."},{"key":"1695_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29\u201336.","journal-title":"Lancet."},{"key":"1695_CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet."},{"key":"1695_CR11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273\u20138.","journal-title":"Ann Oncol."},{"key":"1695_CR12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797\u2013805.","journal-title":"Histopathology."},{"key":"1695_CR13","first-page":"57","volume":"32","author":"H Grabsch","year":"2010","unstructured":"Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value: conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57\u201365.","journal-title":"Cell Oncol."},{"key":"1695_CR14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10620-005-9057-1","volume":"51","author":"DI Park","year":"2006","unstructured":"Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. HER-2\/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371\u20139.","journal-title":"Dig Dis Sci."},{"key":"1695_CR15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","volume":"457","author":"J Ruschoff","year":"2010","unstructured":"Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299\u2013307.","journal-title":"Virchows Arch."},{"key":"1695_CR16","first-page":"235","volume":"118","author":"EY Lee","year":"1994","unstructured":"Lee EY, Cibull ML, Strodel WE, Haley JV. Expression of HER-2\/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med. 1994;118:235\u20139.","journal-title":"Arch Pathol Lab Med."},{"key":"1695_CR17","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.humpath.2007.02.005","volume":"38","author":"MA Kim","year":"2007","unstructured":"Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38:1386\u201393.","journal-title":"Hum Pathol."},{"key":"1695_CR18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.humpath.2008.11.014","volume":"40","author":"AH Marx","year":"2009","unstructured":"Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40:769\u201377.","journal-title":"Hum Pathol."},{"key":"1695_CR19","first-page":"65","volume":"15","author":"T Yano","year":"2006","unstructured":"Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15:65\u201371.","journal-title":"Oncol Rep."},{"key":"1695_CR20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1365-2559.2003.01556.x","volume":"42","author":"C Gulmann","year":"2003","unstructured":"Gulmann C, Butler D, Kay E, Grace A, Leader M. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology. 2003;42:70\u20136.","journal-title":"Histopathology."},{"key":"1695_CR21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/jcp.2010.076570","volume":"63","author":"B Yan","year":"2010","unstructured":"Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, Salto-Tellez M. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839\u201342.","journal-title":"J Clin Pathol."},{"key":"1695_CR22","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.2000.18.11.2201","volume":"18","author":"H Allgayer","year":"2000","unstructured":"Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000;18:2201\u20139.","journal-title":"J Clin Oncol."},{"key":"1695_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000227559","volume":"53","author":"HR Lee","year":"1996","unstructured":"Lee HR, Kim JH, Uhm HD, Ahn JB, Rha SY, Cho JY, Lee JI, et al. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology. 1996;53:192\u20137.","journal-title":"Oncology."},{"key":"1695_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/106689690201000402","volume":"10","author":"J Pinto-de-Sousa","year":"2002","unstructured":"Pinto-de-Sousa J, David L, Almeida R, Leitao D, Preto JR, Seixas M, Pimenta A. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol. 2002;10:247\u201356.","journal-title":"Int J Surg Pathol."},{"key":"1695_CR25","first-page":"604","volume":"44","author":"CT Shun","year":"1997","unstructured":"Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, Wang TH, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology. 1997;44:604\u20139.","journal-title":"Hepatogastroenterology."},{"key":"1695_CR26","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#","volume":"72","author":"S Uchino","year":"1993","unstructured":"Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993;72:3179\u201384.","journal-title":"Cancer."},{"key":"1695_CR27","first-page":"1034","volume":"51","author":"Y Yonemura","year":"1991","unstructured":"Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034\u20138.","journal-title":"Cancer Res."},{"key":"1695_CR28","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00268-009-0142-z","volume":"33","author":"XL Zhang","year":"2009","unstructured":"Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J. Comparative study on overexpression of HER2\/neu and HER3 in gastric cancer. World J Surg. 2009;33:2112\u20138.","journal-title":"World J Surg."},{"key":"1695_CR29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.bjc.6604885","volume":"100","author":"JD Barros-Silva","year":"2009","unstructured":"Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100:487\u201393.","journal-title":"Br J Cancer."},{"key":"1695_CR30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0046-8177(93)90236-A","volume":"24","author":"H Sasano","year":"1993","unstructured":"Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 1993;24:584\u20139.","journal-title":"Hum Pathol."},{"key":"1695_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jso.2930490402","volume":"49","author":"M Tateishi","year":"1992","unstructured":"Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol. 1992;49:209\u201312.","journal-title":"J Surg Oncol."},{"key":"1695_CR32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000227074","volume":"49","author":"Y Yonemura","year":"1992","unstructured":"Yonemura Y, Ninomiya I, Ohoyama S, Fushida S, Kimura H, Tsugawa K, Kamata T, et al. Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology. 1992;49:363\u20137.","journal-title":"Oncology."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-1695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-011-1695-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-1695-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T23:29:07Z","timestamp":1592436547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-011-1695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,6]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1245\/s10434-011-1695-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,6]]}}}